Clinical Trials Browser

INDUSTRY × larotrectinib × Clear all

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms

NCT04142437 2026-04-14

ON-TRK

Recruiting

150 enrolled

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

NCT04945330 2026-04-14

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

Recruiting

100 enrolled

Other solid neoplasm

Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

NCT02122913 2026-02-05

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

Phase 1 Completed

75 enrolled 2 FDA

Other solid neoplasm

Solid Tumors Harboring NTRK Fusion

NCT02637687 2025-06-22

SCOUT

Phase 1/2 Active not recruiting

154 enrolled 2 FDA

Tumor-Agnostic

Neoplasms

NCT05236257 2024-12-10

EPI VITRAKVI

Completed

93 enrolled 14 charts

Sarcoma

Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion

NCT05192642 2023-11-14

A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice

Completed

368 enrolled

Other solid neoplasm

Solid Tumors Harboring NTRK Fusion

NCT03056599 2021-09-24

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

Phase 1 Completed

23 enrolled

Sarcoma

NCT03025360 2019-12-19

Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Approved for marketing

Tumors Harboring NTRK Fusion

Clinical Trials

NAVIGATE

ON-TRK

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

SCOUT

EPI VITRAKVI

A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion